NasdaqGS - Nasdaq Real Time Price USD
Zevra Therapeutics, Inc. (ZVRA)
9.02
+0.17
+(1.92%)
As of 10:37:16 AM EDT. Market Open.
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 7 | 7 |
| Avg. Estimate | 1.27 | -0.07 | 1.09 | 0.64 |
| Low Estimate | -0.12 | -0.1 | -0.34 | 0.05 |
| High Estimate | 2.64 | -0.04 | 2.42 | 1.93 |
| Year Ago EPS | -0.48 | -0.69 | -2.28 | 1.09 |
Revenue Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 6 | 7 | 6 | 7 |
| Avg. Estimate | 22.49M | 24.29M | 93.17M | 161.58M |
| Low Estimate | 20.6M | 22.2M | 87M | 114.6M |
| High Estimate | 24.3M | 26.1M | 99.4M | 232M |
| Year Ago Sales | 4.45M | 3.69M | 23.61M | 93.17M |
| Sales Growth (year/est) | 405.53% | 557.40% | 294.60% | 73.42% |
Earnings History
| Currency in USD | 6/30/2024 | 9/30/2024 | 12/31/2024 | 3/31/2025 |
|---|---|---|---|---|
| EPS Est. | -0.44 | -0.41 | -0.4 | -0.18 |
| EPS Actual | -0.48 | -0.69 | -0.69 | -0.06 |
| Difference | -0.04 | -0.28 | -0.29 | 0.12 |
| Surprise % | -9.92% | -68.29% | -73.12% | 66.93% |
EPS Trend
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | 1.27 | -0.07 | 1.09 | 0.64 |
| 7 Days Ago | 1.11 | -0.05 | 0.95 | 1.37 |
| 30 Days Ago | 0.54 | -0.07 | 0.11 | 0.65 |
| 60 Days Ago | 0.54 | -0.07 | 0.11 | 0.65 |
| 90 Days Ago | -0.15 | -0.08 | 0.04 | 0.89 |
EPS Revisions
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | 2 | 3 | 4 | -- |
| Up Last 30 Days | 2 | 3 | 4 | 3 |
| Down Last 7 Days | 2 | 1 | -- | -- |
| Down Last 30 Days | 1 | 1 | -- | 3 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| ZVRA | 363.99% | 90.06% | 147.87% | -40.97% |
| S&P 500 | 13.08% | 2.49% | 7.56% | 13.96% |
Upgrades & Downgrades
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 5/14/2025 |
| Maintains | Canaccord Genuity: Buy to Buy | 3/13/2025 |
| Maintains | Guggenheim: Buy to Buy | 3/13/2025 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/13/2025 |
| Maintains | Citizens Capital Markets: Market Outperform to Market Outperform | 3/12/2025 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 3/12/2025 |
Related Tickers
SNDX Syndax Pharmaceuticals, Inc.
11.13
-0.58%
KURA Kura Oncology, Inc.
6.38
-0.62%
MCRB Seres Therapeutics, Inc.
7.11
+1.57%
RCUS Arcus Biosciences, Inc.
9.83
-2.09%
ATRA Atara Biotherapeutics, Inc.
8.40
+0.12%
FBIO Fortress Biotech, Inc.
1.8250
-0.82%
TVTX Travere Therapeutics, Inc.
15.35
-0.32%
DAWN Day One Biopharmaceuticals, Inc.
7.03
+0.72%
AMLX Amylyx Pharmaceuticals, Inc.
5.06
-1.24%
INVA Innoviva, Inc.
20.70
+0.49%